The Wall of Remembrance
Father? Husband?
Son? Best mate?
You can remember a friend or relative on this site by adding your message to our unique Wall of Remembrance
Click here to contribute.
Prostate cancer worries?
Concerned about prostate cancer?
An overview of the disease, symptoms, tests and related useful information.
Helping the Prostate Cancer Research Foundation
Make a donation to the William Franklyn Memorial Fund.
Information on how to help the Prostate Cancer Research Foundation, including donating online, organising your own events and leaving a legacy.
Presentations from the 2006 Forum
The delegates from the 2006 Forum
Click on each title to open the presentation as a PDF document:
Prof Jan Trapman (Erasmus University, Netherlands)
The androgen receptor and its target genes in prostate cancer >
Prof Colin Cooper (Institute of Cancer Research, UK)
Tissue microarrays in prostate cancer >
Prof David Dearnaley (Institute of Cancer Research, UK)
Aspects of prostate radiobiology and hypoxia: new therapeutic strategies >
Dr Chris Parker (Institute of Cancer Research, UK)
Predicted natural history of screen detected cancers >
Dr Robert Bristow (University of Toronto, Canada)
Radiation damage: DNA repair biomarkers >
Dr Lisa Cannon-Albright (University of Utah, USA)
Prostate cancer studies in Utah and the 22q locus >
Dr Joanne Edwards (Glasgow Royal Infirmary, UK)
Is the P13k/Akt pathway involved in the development of hormone refractory prostate cancer? >
Mr Alastair Henderson (Frimley Park Hospital, UK)
Patients' experience of treatment: how should we measure >
Don Newling (AstraZeneca, UK)
PSA as a surrogate end point in metastatic prostate cancer >
Dr Nandita de Souza (Institute of Cancer Research, UK)
Application of MR imaging and spectroscopy >
Dr Anthony Tolcher (San Antonio, USA)
Targeting apoptosis in prostate cancer >
Dr Albert Gelet (Edouard Herriot Hospital, FRANCE)
High intenstity focused ultrasound in primary and recurrent cancer >
Prof Chris Bangma (Erasmus MC, NETHERLANDS)
Development of new prostate cancer markers: P.MARK project >
Dr David Agus (Cedars-Sinai MEdical Centre, USA)
HER-Kinase directed therapy >
Prof Hong Wu (UCLA, USA)
PTEN signalling in prostate cancer >
Prof Jack Schalken (Radboud University, NETHERLANDS)
The PRIMA program: identification and validation of new therapeutic targets for prostate cancer >
Prof John Masters (UCL, UK)
Molecular pathology: what will it deliver? >
Dr Jonathan Simons (Winship Cancer Institute, USA)
HIF-1 as a therapeutic target >
Mr Mark Emberton (Institute of Urology, UK)
Photodynamic Therapy >
Prof Matthew Smith (Massachusetts General Hospital, USA)
Modification of skeletal effects of prostate cancer and its treatment >
Dr Peter Albertsen (Farmington, USA)
Natural history of prostate cancer - temporal changes >
Dr Peter Gann (University of Illinois, USA)
Nutritional interventions in prostate cancer >
Prof Yechiel Shai (Weizmann Institute of Science, ISRAEL)
Novel chemotherapeutic peptides for treatment of prostate cancer with a new mode of action - targeting the cell membrane >
Dr Val MacAulay (The Weatherall Institute of Molecular Medicine, UK)
The insulin-like growth factor in prostate cancer >
Dr Gerald Cunha (University of California, USA)
Stromal-epithelial interactions: from model to men >
Dr David Hudson (Institute of Cancer Research, UK)
Prostate stem cells in castration refractory prostate cancer >
Dr James Talcott (Massachusetts General Hospital Cancer Centre, USA)
End points and their significance in early prostate cancer >
Mr Vincent Gnanapragasam (University of Newcastle upon Tyne, UK)
Gonadotropin releasing hormone receptors: clinical relevance? >
Dr Ros Eeles (Institute of Cancer Research, UK)
Familial genetics of prostate cancer, Applications in the clinic >
Dr Eric Schoenmakers (University Medical Centre Nijmegen, NETHERLANDS)
Genome profiling in prostate cancer >
